Apyx Medical (APYX)
(Delayed Data from NSDQ)
$1.38 USD
+0.01 (0.73%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $1.36 -0.02 (-1.45%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.38 USD
+0.01 (0.73%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $1.36 -0.02 (-1.45%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth C Momentum C VGM
Zacks News
Earnings Preview: Apyx Medical (APYX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Breakout Stocks for Impressive Returns
by Nitish Marwah
SB, VTSI, FENC and APYX qualified the screen for breakout stocks for today.
Apyx (APYX) Moves 10.9% Higher: Will This Strength Last?
by Zacks Equity Research
Apyx (APYX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Apyx Medical (APYX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of 14.29% and 25.27%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Apyx Medical (APYX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of 0.00% and 9.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Apyx Medical (APYX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of 69.23% and 3.28%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Apyx Medical (APYX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apyx (APYX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Medtronic's (MDT) Midas Rex Drills Completes First U.S. Surgery
by Zacks Equity Research
Medtronic's (MDT) recent surgeries reach a milestone in the transformation of spine surgery as a result of increased accuracy and minimally invasive technique.
Illumina (ILMN) Sequencing & Microarray Sales Hurt by Pandemic
by Zacks Equity Research
Seasonality in DTC functionality also continues to erode Illumina's (ILMN) microarray sales.
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical
BD (BDX) Gets EUA, CE Mark for New Molecular Diagnostic Test
by Zacks Equity Research
BD's (BDX) new test has the capability to detect SARS-CoV-2 and Influenza A+B in a single test.
Apyx Medical's (APYX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Apyx Medical (APYX).
Here's Why Momentum Investors Will Love Apyx Medical (APYX)
by Zacks Equity Research
Does Apyx Medical (APYX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Hill-Rom (HRC) to Boost Cardiology Portfolio with New Buyout
by Zacks Equity Research
Hill-Rom's (HRC) acquisition of Bardy Diagnostics enables the former to expand into ambulatory cardiac monitoring space to accelerate digital health offering.
Apyx (APYX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Apyx (APYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Apyx (APYX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Apyx (APYX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Apyx Medical (APYX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of 18.75% and 3.33%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Apyx Medical (APYX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apyx Medical (APYX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of 17.65% and 71.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Apyx Medical (APYX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NanoString Technologies (NSTG) Surges: Stock Moves 10.3% Higher
by Zacks Equity Research
NanoString Technologies (NSTG) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.